Aibo Medical Robotics Showcases Groundbreaking Remote Neurointerventional Surgery at OCIN 2022

On December 17, from 15:30 to 16:00, Professor Liu Jianmin’s team from the First Affiliated Hospital of Naval Medical University (Changhai Hospital) successfully and efficiently performed a neurointerventional procedure. In the presence of numerous cerebrovascular experts both online and offline at the OCIN conference held at the Shanghai International Convention Center, the team operated the neurointerventional surgical robot developed by Shenzhen Aibo Medical Robot Co., Ltd. (hereinafter referred to as “Aibo Medical Robot”) to remotely control the surgical robot located at the Surgical Training Center of Changhai Hospital.

The live surgical broadcast is a key segment of the Oriental Conference on Interventional Neurology (OCIN), serving as a premier platform for leading domestic and international experts in cerebrovascular diseases to perform live surgeries and exchange experiences. For the first time at this OCIN conference, the live broadcast featured the remote transmission of neurointerventional robotic surgery to the onsite venue, enabling attending experts to witness firsthand and up close the value delivered by the most advanced innovative products in neurointerventional robotic surgery.

Changhai Hospital Training Center DSA Catheterization Laboratory

Before the live broadcast began, the staff had quickly installed Aibo’s surgical robot onto the operating table and completed procedures such as puncture and sheath insertion.

 Changhai Hospital Training Center: DSA Operating Room Robotic Surgery Site

After the live broadcast began, Professor Zhang Yongxin from Professor Liu Jianmin’s team operated the neurointerventional surgical robot console of Aibo Medical Robot in the DSA suite of the Training Center at Changhai Hospital, demonstrating to the online guestsLive StreamingDemonstrated procedures such as superselective catheterization of the bilateral common carotid arteries and vertebral arteries. On the live broadcast screen, guests both on-site and off-site could clearly see Professor Zhang Yongxin operating via the Aibo controllerPrecise control over guidewire and catheter maneuvers, including advancement, retraction, and rotation.Just as in the past, manipulating catheters and guidewires on the operating table. Only this time,He did not wear lead aprons; seated outside the operating room in a radiation-free environment, he easily and rapidly completed the entire surgical procedure.

Professor Liu Jianmin Performs Remote Surgery at the Oriental Conference (I)

Subsequently, Professor Zhang Yongxin transferred the surgical control to the conference venue.Professor Liu Jianmin, located at the Shanghai International Convention Center (the site of the OCIN 2022 conference) dozens of kilometers away, remotely manipulated the guidewire and catheter using the operator console of AiBo Medical Robot’s neurointerventional surgical robot.Partial completion of guidewire catheterization in the porcine carotid and subclavian arteriesAdvance, Rotate, Withdrawmaneuvers, rapidly completing the most challenging superselective catheterization during the angiography procedure; the entire processNo significant delay was observed (Professor Liu Jianmin stated on-site that he could not perceive any latency)., with clean, precise, and highly fluid maneuvers. During this process, Professor Liu Jianmin also utilized Aibo’s proprietary features, such as wire-catheter联动 (wire-catheter coordination), to achieve efficient removal of the guidewire and catheter.

Professor Liu Jianmin Conducts Remote Surgery at the Oriental Congress (II)

Following the live broadcast of the remote surgery, experts both online and offline engaged in a lively discussion regarding their viewing experience, operational insights, and developments in the field of neurointerventional surgical robotics. The session was moderated by Professor Yang Pengfei from Changhai Hospital.

“Vascular interventional surgical robots are already available abroad, but not yet in China, which is something we greatly anticipate... The core maneuvers in vascular interventional procedures involve the ‘advancement/retraction/rotation of guidewires and catheters, as well as combined movements of advancement/retraction plus rotation.’ Aibo’s master-side control interface closely aligns with physicians’ established habits in manipulating guidewires and catheters during surgery...”

——Professor Liu Jianmin, Changhai Hospital

“It was my first time witnessing robotic remote surgery, and it was truly awe-inspiring... Today’s live broadcast has convinced me of the viability of vascular interventional surgical robots and remote surgery...”

——Professor Liu Sheng, Jiangsu Province Hospital

“Regrettably, I was unable to be present on-site due to home isolation... The remote operation of the vascular interventional surgical robot by Aibo enabled me to perform the surgery from home...”

— Professor Cheng Guangsen, Zhuhai People's Hospital

“I share the same sentiment as Professor Liu Sheng. Seeing it for the first time was truly astonishing—the surgery was performed entirely through remote operation. Furthermore, the innovations pioneered by Director Liu’s team are deeply moving and truly impressive...”

—Professor Zhang Quanbin, Shanghai Tenth People’s Hospital

“I have long anticipated the advent of neurointerventional robots in the field of endovascular intervention. It has finally made its debut, featuring a live demonstration of remote surgical capabilities... Excellent. Many thanks to all who participated...”

——Professor Sun Jun, Wenzhou Central Hospital

“As you can see, our team performed robotic surgery at the operative site, completing the key surgical steps within three to five minutes—a highly efficient process... The remote operation also felt virtually latency-free... We have already scheduled the initiation of registered human clinical trials around the Lunar New Year period.”

——Professor Yang Pengfei, Changhai Hospital

Prof. Yang Pengfei of Changhai Hospital Presided Over the Conference Discussion

In response to the discussions and questions raised by the experts, Guo Jian, Co-founder and General Manager of Aibo Medical Robotics, provided a brief overview of the company’s background, technological expertise, product development philosophy, as well as the planning and progress of its pan-vascular interventional surgical robot. He also expressed his gratitude to Professor Liu Jianmin’s team at Changhai Hospital and the experts from the clinical sub-centers.

Finally, Professor Liu Jianmin from Changhai Hospital, the principal investigator for Aibo Neurointerventional, delivered concluding remarks centered on the spirited discussions among experts both online and offline.

“The future development potential of robotics in the field of neurointervention is immense. Such high-tech innovations, which we may have previously only encountered in news reports, are now being applied to save patients’ lives—a truly remarkable advancement. I believe that applying these significant inventions to the medical field and to human life will generate and unleash even greater value. Aibot’s first-generation product is already in the clinical stage, and the next-generation pan-vascular interventional surgical robot, equipped with enhanced therapeutic capabilities, is also on its way!”

——Professor Liu Jianmin, Changhai Hospital

 Professor Liu Jianmin of Changhai Hospital Provided Comments and Summary

As a pioneer and leader in the field of pan-vascular interventional surgical robots, Aibo Medical Robotics has consistently adhered to the product development philosophy of “From the doctors, By the engineers, For the patients.” The company engages in deep medical-engineering integration with top-tier clinical medical centers, including the Cerebrovascular Disease Center at Shanghai Changhai Hospital, the Department of Cardiology, and the Department of Vascular Surgery at Shanghai Zhongshan Hospital, dedicating itself to developing vascular interventional surgical robots that meet clinical needs.

Aibo Medical’s neurointerventional surgical robot made its official debut at OCIN 2022. The robotic surgery was livestreamed by Professor Liu Jianmin’s team from Changhai Hospital, along with a live demonstration of remote operation at the conference venue, earning high acclaim from attending experts and fully showcasing Aibo Medical’s technological prowess and product strength.

The Oriental Conference on Interventional Neurology (OCIN) is a prestigious conference in the field of cerebrovascular diseases, renowned both domestically and internationally. With a distinguished history spanning two decades, it has become one of the most significant forces driving the vigorous development of China’s cerebrovascular disease initiatives. Professor Liu Jianmin from Changhai Hospital serves as the Conference Chair. Adhering to its core mission of “Exchange, Cooperation, Standardization, and Innovation,” OCIN connects peers worldwide to build a comprehensive platform for academic exchange, clinical research, and medical-engineering translation, continuously exploring new frontiers and striving for excellence. OCIN 2022 was hosted by the Shanghai Medical Association and its Stroke Specialty Branch, organized by Shanghai Changhai Hospital, and held from December 15 to 18, 2022, at the Shanghai International Convention Center in a hybrid format combining online and offline participation.

Shenzhen Aibo Medical Robot Co., Ltd. (hereinafter referred to as “Aibo Medical Robot”) is a high-tech enterprise specializing in medical robotics, founded by Professor Guo Shuxiang—a distinguished expert under the Overseas High-Level Talent Introduction Program, Foreign Member of the Japan Academy of Engineering, and IEEE Fellow—along with his team. The company’s core technological achievements stem from China’s National “863 Program.” As of October 2022, Aibo Medical Robot had filed over 300 intellectual property rights, including Chinese invention patents and international patents, with multiple original technologies reaching internationally leading levels. The company has established collaborations with renowned clinical expert teams in the field of vascular intervention in China and has secured investments from several top-tier venture capital firms.